华润医药(03320.HK) 宣布,旗下“华润双鹤”司美格鲁肽注射液降糖适应症完成Ⅲ期临床试验登记公示。据介绍,司美格鲁肽注射液适用于成人2型糖尿病患者的血糖控制,在饮食控制和运动基础上,接受二甲双胍和/或磺脲类药物治疗血糖仍控制不佳的成人2型糖尿病患者。(hc/da)(港股报价延迟最少十五分钟。沽空资料截至 2026-04-28 16:25。)AASTOCKS新闻
Source Link华润医药(03320.HK) 宣布,旗下“华润双鹤”司美格鲁肽注射液降糖适应症完成Ⅲ期临床试验登记公示。据介绍,司美格鲁肽注射液适用于成人2型糖尿病患者的血糖控制,在饮食控制和运动基础上,接受二甲双胍和/或磺脲类药物治疗血糖仍控制不佳的成人2型糖尿病患者。(hc/da)(港股报价延迟最少十五分钟。沽空资料截至 2026-04-28 16:25。)AASTOCKS新闻
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.